Citigroup’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $71.7M | Buy |
316,217
+234,906
| +289% | +$41.8M | 0.02% | 593 |
|
|
2026
Q1 | $14M | Buy |
81,311
+32,372
| +66% | +$6M | 0.01% | 1268 |
|
|
2025
Q4 | $9.76M | Buy |
48,939
+13,101
| +37% | +$2.38M | ﹤0.01% | 1554 |
|
|
2025
Q3 | $5.61M | Sell |
35,838
-110,759
| -76% | -$17.6M | ﹤0.01% | 1892 |
|
|
2025
Q2 | $22.2M | Sell |
146,597
-87,913
| -37% | -$11.7M | 0.01% | 913 |
|
|
2025
Q1 | $35.3M | Sell |
234,510
-10,150
| -4% | -$1.7M | 0.02% | 705 |
|
|
2024
Q4 | $45.2M | Buy |
244,660
+8,519
| +4% | +$1.64M | 0.03% | 560 |
|
|
2024
Q3 | $46.5M | Buy |
236,141
+22,788
| +11% | +$4.74M | 0.03% | 557 |
|
|
2024
Q2 | $44.1M | Buy |
213,353
+10,736
| +5% | +$2.43M | 0.03% | 541 |
|
|
2024
Q1 | $54.9M | Buy |
202,617
+20,918
| +12% | +$5M | 0.04% | 443 |
|
|
2023
Q4 | $43M | Buy |
181,699
+95,203
| +110% | +$18.7M | 0.03% | 520 |
|
|
2023
Q3 | $17M | Buy |
86,496
+65,922
| +320% | +$13.5M | 0.01% | 856 |
|
|
2023
Q2 | $4.33M | Sell |
20,574
-9,146
| -31% | -$1.82M | ﹤0.01% | 1589 |
|
|
2023
Q1 | $6M | Buy |
29,720
+10,830
| +57% | +$2.45M | ﹤0.01% | 1402 |
|
|
2022
Q4 | $4.12M | Sell |
18,890
-12,533
| -40% | -$2.74M | ﹤0.01% | 1564 |
|
|
2022
Q3 | $6.18M | Buy |
31,423
+13,001
| +71% | +$2.81M | ﹤0.01% | 1426 |
|
|
2022
Q2 | $3.94M | Sell |
18,422
-4,143
| -18% | -$1.01M | ﹤0.01% | 1671 |
|
|
2022
Q1 | $6.41M | Sell |
22,565
-1,907
| -8% | -$588K | ﹤0.01% | 1533 |
|
|
2021
Q4 | $9.22M | Sell |
24,472
-27,480
| -53% | -$10.7M | ﹤0.01% | 1431 |
|
|
2021
Q3 | $21.4M | Buy |
51,952
+4,132
| +9% | +$1.72M | 0.01% | 951 |
|
|
2021
Q2 | $17.7M | Buy |
47,820
+25,389
| +113% | +$8.48M | 0.01% | 1066 |
|
|
2021
Q1 | $6.5M | Buy |
22,431
+11,258
| +101% | +$3.13M | ﹤0.01% | 1628 |
|
|
2020
Q4 | $2.79M | Sell |
11,173
-657
| -6% | -$156K | ﹤0.01% | 2544 |
|
|
2020
Q3 | $2.68M | Sell |
11,830
-8,987
| -43% | -$1.87M | ﹤0.01% | 2389 |
|
|
2020
Q2 | $3.63M | Sell |
20,817
-1,371
| -6% | -$219K | ﹤0.01% | 2166 |
|
|
2020
Q1 | $2.8M | Buy |
22,188
+6,624
| +43% | +$993K | ﹤0.01% | 2170 |
|
|
2019
Q4 | $2.38M | Sell |
15,564
-1,981
| -11% | -$274K | ﹤0.01% | 2794 |
|
|
2019
Q3 | $2.32M | Sell |
17,545
-28,059
| -62% | -$3.76M | ﹤0.01% | 2692 |
|
|
2019
Q2 | $6.47M | Buy |
45,604
+28,090
| +160% | +$3.81M | 0.01% | 1760 |
|
|
2019
Q1 | $2.54M | Sell |
17,514
-7,164
| -29% | -$941K | ﹤0.01% | 2424 |
|
|
2018
Q4 | $2.79M | Sell |
24,678
-7,225
| -23% | -$905K | ﹤0.01% | 2352 |
|
|
2018
Q3 | $4.29M | Sell |
31,903
-308
| -1% | -$38K | ﹤0.01% | 2004 |
|
|
2018
Q2 | $3.62M | Buy |
32,211
+971
| +3% | +$105K | ﹤0.01% | 2140 |
|
|
2018
Q1 | $3.33M | Sell |
31,240
-7,039
| -18% | -$759K | ﹤0.01% | 2141 |
|
|
2017
Q4 | $4.19M | Buy |
38,279
+23,520
| +159% | +$2.56M | ﹤0.01% | 2000 |
|
|
2017
Q3 | $1.59M | Buy |
14,759
+899
| +6% | +$92.4K | ﹤0.01% | 2901 |
|
|
2017
Q2 | $1.4M | Sell |
13,860
-4,033
| -23% | -$371K | ﹤0.01% | 2958 |
|
|
2017
Q1 | $1.61M | Sell |
17,893
-6,278
| -26% | -$533K | ﹤0.01% | 2690 |
|
|
2016
Q4 | $1.84M | Sell |
24,171
-1,944
| -7% | -$148K | ﹤0.01% | 3050 |
|
|
2016
Q3 | $2.18M | Buy |
26,115
+12,242
| +88% | +$1.03M | ﹤0.01% | 2435 |
|
|
2016
Q2 | $1.14M | Buy |
13,873
+4,970
| +56% | +$409K | ﹤0.01% | 2823 |
|
|
2016
Q1 | $676K | Sell |
8,903
-11,196
| -56% | -$829K | ﹤0.01% | 3794 |
|
|
2015
Q4 | $1.62M | Buy |
20,099
+19,634
| +4,222% | +$1.42M | ﹤0.01% | 2651 |
|
|
2015
Q3 | $30K | Sell |
465
-4,083
| -90% | -$293K | ﹤0.01% | 5741 |
|
|
2015
Q2 | $320K | Sell |
4,548
-6,971
| -61% | -$516K | ﹤0.01% | 4085 |
|
|
2015
Q1 | $913K | Buy |
11,519
+434
| +4% | +$32K | ﹤0.01% | 3168 |
|
|
2014
Q4 | $706K | Sell |
11,085
-13,806
| -55% | -$865K | ﹤0.01% | 3520 |
|
|
2014
Q3 | $1.49M | Buy |
24,891
+15,795
| +174% | +$904K | ﹤0.01% | 2761 |
|
|
2014
Q2 | $487K | Sell |
9,096
-9,922
| -52% | -$544K | ﹤0.01% | 3480 |
|
|
2014
Q1 | $1.15M | Sell |
19,018
-3,254
| -15% | -$190K | ﹤0.01% | 2769 |
|
|
2013
Q4 | $1.18M | Buy |
22,272
+18,101
| +434% | +$909K | ﹤0.01% | 3026 |
|
|
2013
Q3 | $193K | Sell |
4,171
-1,993
| -32% | -$91.5K | ﹤0.01% | 4181 |
|
|
2013
Q2 | $253K | Buy |
+6,164
| New | +$264K | ﹤0.01% | 4075 |
|
Other funds holding CRL
AI
Citigroup's CRL Position: Q2 2026 in Review
Citigroup increased its Charles River Laboratories (CRL) stake by 289% in Q2 2026, buying an estimated $41.8M and bringing the position to 316,217 shares worth $71.7M. The position accounts for 0.02% of the portfolio, ranked #593.
Citigroup first reported a position in CRL in Q2 2013 and has held it in 53 quarters since. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Citigroup held 316,217 shares of Charles River Laboratories worth $71.7M as of Q2 2026.
- Citigroup bought 234,906 Charles River Laboratories shares in Q2 2026, an estimated $41.8M.
- Charles River Laboratories made up 0.02% of Citigroup's portfolio in Q2 2026, its #593 holding.
- Citigroup first reported a position in Charles River Laboratories in Q2 2013 and has held it in 53 quarters since.
- 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.